
Quarterly report 2025-Q3
added 11-13-2025
Onconova Therapeutics Net Debt 2011-2026 | ONTX
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Onconova Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -19 M | -22.7 M | -17 M | -4.02 M | -21.4 M | -19.8 M | -43.6 M | -60 M | -81.5 M | -2.71 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.71 M | -81.5 M | -29.2 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Anika Therapeutics
ANIK
|
-46 M | $ 14.93 | 0.88 % | $ 219 M | ||
|
Aptorum Group Limited
APM
|
-2.77 M | $ 0.93 | 0.51 % | $ 5.07 M | ||
|
Aquestive Therapeutics
AQST
|
-75.5 M | $ 4.14 | 0.36 % | $ 443 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
-206 M | $ 8.39 | 4.5 % | $ 230 M | ||
|
Ardelyx
ARDX
|
136 M | $ 6.06 | 1.94 % | $ 1.46 B | ||
|
argenx SE
ARGX
|
-89.9 M | $ 749.68 | 0.44 % | $ 25 B | ||
|
Arcutis Biotherapeutics
ARQT
|
65.3 M | $ 23.93 | 1.27 % | $ 3.04 B | ||
|
Arvinas
ARVN
|
-141 M | $ 11.36 | 4.7 % | $ 805 M | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
-115 M | $ 61.99 | 1.57 % | $ 8.29 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B | ||
|
Assembly Biosciences
ASMB
|
-55.8 M | $ 29.09 | 0.28 % | $ 326 M | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Actinium Pharmaceuticals
ATNM
|
-46.3 M | $ 1.13 | 15.26 % | $ 35.3 M | ||
|
Atossa Therapeutics
ATOS
|
-39.6 M | $ 5.19 | -3.36 % | $ 44.7 M | ||
|
Atara Biotherapeutics
ATRA
|
1.89 M | $ 5.0 | 0.2 % | $ 62.7 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Aurinia Pharmaceuticals
AUPH
|
-26.8 M | $ 16.05 | 2.79 % | $ 2.16 B | ||
|
Autolus Therapeutics plc
AUTL
|
-32.7 M | $ 1.41 | -0.35 % | $ 375 M | ||
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
Axon Enterprise
AXON
|
-404 M | $ 411.97 | -0.2 % | $ 31.2 B | ||
|
Aytu BioScience
AYTU
|
-19.9 M | $ 2.65 | -1.12 % | $ 16.6 M | ||
|
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
-31.2 M | - | 1.93 % | $ 17.4 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
BioCardia
BCDA
|
-1.97 M | $ 1.18 | -1.67 % | $ 7.87 M | ||
|
BioCryst Pharmaceuticals
BCRX
|
211 M | $ 9.59 | 6.26 % | $ 1.98 B | ||
|
Allena Pharmaceuticals
ALNA
|
-29.5 M | - | 3.16 % | $ 1.9 M | ||
|
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
-3.44 M | - | 10.36 % | $ 9.8 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
-22.2 M | $ 3.05 | 1.51 % | $ 260 M | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
455 M | $ 9.46 | -3.47 % | $ 612 M | ||
|
BioVie
BIVI
|
-17.2 M | $ 1.46 | 2.81 % | $ 2.16 M | ||
|
BioLineRx Ltd.
BLRX
|
-13.9 M | $ 2.32 | 4.98 % | $ 908 M | ||
|
BioMarin Pharmaceutical
BMRN
|
-1.3 B | $ 56.04 | 0.96 % | $ 10.7 B | ||
|
BioNTech SE
BNTX
|
-973 M | $ 91.64 | 0.5 % | $ 27.2 B | ||
|
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | ||
|
BioXcel Therapeutics
BTAI
|
56.3 M | $ 1.18 | -0.42 % | $ 14.4 M | ||
|
Burford Capital Limited
BUR
|
-135 M | $ 4.5 | 8.57 % | $ 683 M |